Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5173384 | 0.93 | HTR1A (0.48) | HTR1AMTNR1AMTNR1BENPP2HTR2B | |
| SCHEMBL5175120 | 0.89 | HTR1A (0.54) | HTR1AMTNR1AMTNR1BENPP2NQO2 | |
| SCHEMBL10407585 | 0.86 | HTR1A (0.54) | HTR1AMTNR1AMTNR1BENPP2HTR2B | |
| SCHEMBL9669326 | 0.82 | HTR1A (0.58) | HTR1AMTNR1AMTNR1BENPP2HTR2B | |
| SCHEMBL5223857 | 0.81 | MTNR1A (0.72) | HTR1AMTNR1AMTNR1BNQO2 | |
| SCHEMBL5173919 | 0.81 | KDM4C (0.48) | HTR1AMTNR1AMTNR1BHTR2BSIGMAR1 | |
| SCHEMBL30671706 | 0.80 | HTR1A (0.56) | HTR1AMTNR1AMTNR1BENPP2HTR2B | |
| SCHEMBL5229125 | 0.80 | HTR1A (0.53) | HTR1AMTNR1AMTNR1BENPP2HTR2B | |
| SCHEMBL5175500 | 0.80 | HTR1A (0.56) | HTR1AMTNR1AMTNR1BENPP2HTR2B | |
| SCHEMBL7022012 | 0.79 | MTNR1A (0.57) | HTR1AMTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| US-4977166-A | ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | RHONE-POULENC SANTE (FR) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | HTR1A 660/4885MTNR1A 2122/4885MTNR1B 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.